Literature DB >> 3258584

Killing of human myelomonocytic leukemia and lymphocytic cell lines by Actinobacillus actinomycetemcomitans leukotoxin.

D L Simpson1, P Berthold, N S Taichman.   

Abstract

The purified leukotoxin of Actinobacillus actinomycetemcomitans kills human leukemic cell lines (e.g., HL-60, U937, and KG-1) and human T- and B-cell lines (e.g., JURKAT, MOLT-4, Daudi, and Raji) in a dose- and time-dependent manner. The 50% effective doses for these cell lines are similar to those established for human polymorphonuclear leukocytes and monocytes. In contrast, other human and nonhuman tumor cell lines are not susceptible to the leukotoxin. These human leukemia and lymphoid cell lines will serve as useful model systems with which to study the molecular specificity and mechanism(s) of action of the actinobacillus leukotoxin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258584      PMCID: PMC259778          DOI: 10.1128/iai.56.5.1162-1166.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Comparative studies on the biology of Actinobacillus actinomycetemcomitans leukotoxin in primates.

Authors:  N S Taichman; D L Simpson; S Sakurada; M Cranfield; J DiRienzo; J Slots
Journal:  Oral Microbiol Immunol       Date:  1987-09

3.  Monoclonal antibodies to leukotoxin of Actinobacillus actinomycetemcomitans.

Authors:  J M DiRienzo; C C Tsai; B J Shenker; N S Taichman; E T Lally
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

4.  Leukotoxic effects of Actinobacillus actinomycetemcomitans. Modulation by serum components.

Authors:  W P McArthur; C C Tsai; P C Baehni; R J Genco; N S Taichman
Journal:  J Periodontal Res       Date:  1981-03       Impact factor: 4.419

5.  Studies of leukotoxin from Actinobacillus actinomycetemcomitans using the promyelocytic HL-60 cell line.

Authors:  J J Zambon; C DeLuca; J Slots; R J Genco
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Biochemical and morphological characterization of the killing of human monocytes by a leukotoxin derived from Actinobacillus actinomycetemcomitans.

Authors:  N S Taichman; R T Dean; C J Sanderson
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

7.  Extraction and isolation of a leukotoxin from Actinobacillus actinomycetemcomitans with polymyxin B.

Authors:  C C Tsai; B J Shenker; J M DiRienzo; D Malamud; N S Taichman
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

8.  Serum neutralizing activity against Actinobacillus actinomycetemcomitans leukotoxin in juvenile periodontitis.

Authors:  C C Tsai; W P McArthur; P C Baehni; C Evian; R J Genco; N S Taichman
Journal:  J Clin Periodontol       Date:  1981-08       Impact factor: 8.728

9.  Leukotoxicity of an extract from Actinobacillus actinomycetemcomitans for human gingival polymorphonuclear leukocytes.

Authors:  N S Taichman; J M Wilton
Journal:  Inflammation       Date:  1981-03       Impact factor: 4.092

Review 10.  Membrane receptors for bacterial toxins.

Authors:  L Eidels; R L Proia; D A Hart
Journal:  Microbiol Rev       Date:  1983-12
View more
  28 in total

1.  Separable domains define target cell specificities of an RTX hemolysin from Actinobacillus pleuropneumoniae.

Authors:  D R McWhinney; Y F Chang; R Young; D K Struck
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

2.  Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.

Authors:  Kristina M DiFranco; Rajesh H Kaswala; Chandni Patel; Chinnaswam Kasinathan; Scott C Kachlany
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

3.  Effects of cations and osmotic protectants on cytolytic activity of Actinobacillus actinomycetemcomitans leukotoxin.

Authors:  M Iwase; E T Lally; P Berthold; H M Korchak; N S Taichman
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  Actinobacillus actinomycetemcomitans leukotoxin requires lipid microdomains for target cell cytotoxicity.

Authors:  Karen P Fong; Cinthia M F Pacheco; Linda L Otis; Somesh Baranwal; Irene R Kieba; Gerald Harrison; Elliot V Hersh; Kathleen Boesze-Battaglia; Edward T Lally
Journal:  Cell Microbiol       Date:  2006-07-07       Impact factor: 3.715

Review 5.  Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy.

Authors:  S C Kachlany
Journal:  J Dent Res       Date:  2010-03-03       Impact factor: 6.116

6.  Cloning and expression of the leukotoxin gene from Actinobacillus actinomycetemcomitans.

Authors:  D Kolodrubetz; T Dailey; J Ebersole; E Kraig
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

Review 7.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

8.  Caspase 1 involvement in human monocyte lysis induced by Actinobacillus actinomycetemcomitans leukotoxin.

Authors:  P Kelk; A Johansson; R Claesson; L Hänström; S Kalfas
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Use of monoclonal antibodies with neutralizing effects on toxic antigens from human bacterial plaque to detect specific bacteria by colony blotting.

Authors:  M Levine; F C Miller
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

10.  Lethal effects of Actinobacillus actinomycetemcomitans leukotoxin on human T lymphocytes.

Authors:  D F Mangan; N S Taichman; E T Lally; S M Wahl
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.